The transmembrane tyrosine kinase HER2 (ErbB2, neu) is a prototypical biomarker for breast cancers and a therapeutic target. Although anti-HER2 therapies are remarkably effective, HER2-positive tumors are heterogeneous and some subtypes do not respond or develop resistance to these therapies. Here we show that H2NTF, a novel N-terminal fragment of HER2, is expressed at variable levels in 60% of the breast cancer samples analyzed. Characterization of H2NTF shows that it is devoid of the tyrosine kinase domain but it readily interacts with full-length HER2 and other HER receptors. As a consequence, H2NTF acts as a dominantnegative, attenuating the signaling triggered by full-length HER receptors. Expression of H2NTF results in resistance to the treatment with low concentrations of trastuzumab in vitro. However, cells expressing H2NTF and non-expressing cells have similar sensitivity to trastuzumab in vivo, indicating that H2NTF/trastuzumab complexes trigger antibody-dependent cell-mediated cytotoxicity.
INTRODUCTION
A type of breast cancer is characterized by the expression of high levels of the transmembrane tyrosine kinase HER2 (ErbB2, neu). HER2 is structurally similar and functionally related to three tyrosine kinase receptors: the epidermal growth factor receptor (EGFR, HER1, ErbB1), HER3 and HER4 (ErbB3, ErbB4). 1 The epidermal growth factor (EGF) is the prototype of a family of ligands that include the transforming growth factor-alpha, which binds to HER1, and heregulin (HRG), which binds to HER3 and HER4. The binding of epidermal growth factor-like ligands to their cognate receptors induces conformational changes in the latter. These conformational changes result in exposure of the dimerization domain and subsequent homo-or heterodimerization of HER receptors. Receptor dimerization leads to the activation of the intracellular tyrosine kinases, which initiate signaling cascades, including the mitogen-activated protein kinase and the phosphoinositide 3-kinase pathways, that control the regulation of the cell proliferation, differentiation and motility. 2 Although HER2 does not bind any ligand, because of the constitutive exposure of its dimerization domain, it is the preferred partner for heterodimerization. In fact, some authors consider HER2 as an amplifier of the HER receptor pathway rather than a bona fide receptor. 3 Two types of specific drugs are currently available to treat HER2-positive breast cancers: monoclonal antibodies against the extracellular domain of the receptor (such as trastuzumab, also known as herceptin) and small-molecule tyrosine kinase inhibitors (such as lapatinib, also known as tykerb). 4 The mechanism of action of trastuzumab is complex and includes inhibition of HER2 signaling as well as antibody-dependent cell-mediated cytotoxicity (ADCC), carried out by macrophages and natural killer cells. 5 Despite the undeniable success that the anti-HER2 therapies have represented, a substantial proportion of advanced HER2-positive breast tumors either do not respond to anti-HER2 therapies or develop resistance against them. 1 Therefore, understanding the mechanisms of resistance against anti-HER2 therapies remains a current challenge.
A subgroup of HER2-positive breast tumors express a series of carboxy-terminal fragments of HER2 collectively known as HER2 CTFs or p95HER2. 6 Compared with tumors with undetectable levels of these fragments, p95HER2-positive tumors have worse prognosis and tend to be resistant to the treatment with trastuzumab. 7 One of the fragments, 100-115 kDa p95HER2 (also known as 611-CTF), is a constitutively active form of HER2 because of its ability to form dimers maintained by intermolecular disulfide bonds. 8 Recently, specific antibodies against 100-115 kDa p95HER2 have been developed. 9, 10 Under non-denaturing conditions, these antibodies recognize epitopes exposed in the fragment but masked in the full-length HER2 molecule.
During the characterization of the HER2 species recognized by the anti-p95HER2 antibodies under denaturing conditions, we observed the existence of a novel N-terminal fragment of HER2 (or H2NTF, for short) frequently expressed in breast tumor samples. H2NTF is expressed at variable levels in 60% of the breast cancer samples analyzed. Characterization of H2NTF shows that it is devoid of the tyrosine kinase domain but it readily interacts with full-length HER2 and other HER receptors. As a consequence, H2NTF acts as a dominant negative, attenuating the signaling triggered by full-length HER receptors. Expression of H2NTF results in resistance to the treatment with low concentrations of trastuzumab in vitro. However, cells expressing H2NTF and nonexpressing cells have similar sensitivity to trastuzumab in vivo, likely because H2NTF/trastuzumab complexes trigger ADCC.
RESULTS
Breast tumors express variable levels of a HER2 amino-terminal fragment (H2NTF) Confirming previous results, 8 western blot analysis of HER2-positive breast cancer samples with CB11, an antibody against the intracellular domain of HER2, shows the presence of a group of carboxy-terminal fragments, collectively known as p95HER2 or CTFs (Figure 1a, upper panel, and 1b) . Analysis of the same samples with L87 or 32H2, two antibodies against epitopes located in the extracellular domain of HER2, revealed the existence of a HER2 species of B110 kDa, hereafter referred to as H2NTF ( Figure 1a and Supplementary Figure S1A ).
To rule out that the fragments observed were artifacts generated during the homogenization and lysis of the tumor specimens, we incubated freshly obtained homogenates at 37 1C in the absence of protease inhibitors. Even after 24 h of incubation, no degradation of HER2 or variations in the levels of p95HER2 or H2NTF, were observed (Supplementary Figure S1B) . We concluded that H2NTF was present in the original breast cancer samples.
We extended the analysis of H2NTF levels to 75 HER2-positive breast cancer samples. The N-terminal species was observed at detectable levels in 48 (60.7%) of the cases. The ratio H2NTF/HER2 varied from 0.1 (Figure 1a, Table SI) .
Despite its frequent presence in breast cancer samples, we failed to identify high levels of the H2NTF in a panel of HER2-positive cancer cell lines (Figure 1c ), raising the possibility that the tumor environment is required for the effective generation of this HER2 fragment.
In summary, the results in Figure 1 show the existence of N-terminal fragments of HER2 frequently expressed in breast cancers.
H2NTFs is a group of fragments devoid of tyrosine kinase activity As a first step to map the C-terminus of the H2NTF, we introduced a series of premature stop codons in the sequence encoding fulllength HER2 after the amino acids indicated in Figure 2a . The resulting proteins mimicked the products of HER2 cleavage by caspases and calpains, proteases that have been suggested to cleave the intracellular domain of HER2. [11] [12] [13] [14] [15] [16] [17] [18] To functionally characterize these constructs, we used the highly transfectable cell line HEK293.
Transient transfection of HER2 into HEK293 cells led to the robust activation of Erk1,2 ( Figure 2b ). The ability to activate the Erk1,2 pathway was impaired by truncation of HER2 after the D1125 and D1087 residues, whereas, as expected, shorter H2NTFs were completely inactive (Figure 2b) .
Comparison of the electrophoretic migration of the different HER2 truncations with that of the H2NTF from a tumor sample, untreated or deglycosilated, showed that the migration of the HER2 fragment ending at D742 was similar to that of the HER2 N-terminal fragment present in breast cancer samples (Figure 2c ). We concluded that the H2NTF is a truncated HER2 form that lacks most of the intracellular domain, including the kinase domain.
Next, we stably transfected the H2NTF742 into cell lines derived from HER2 overexpressing and non-overexpressing tumors, BT474 and MCF7 cells, respectively ( Figure 2d ). Analysis of the subcellular localization of H2NTF742 indicated that similar to full-length HER2, it was preferentially localized at the cell surface ( Figure 2e ). This result strongly suggests that, despite lacking most of the cytoplasmic domain, H2NTF742 is correctly folded. Otherwise, the fragment would be located at the early secretory pathway, where quality-control mechanisms retain and degrade misfolded proteins. 19 To further validate that H2NTF742 is a good model for the H2NTF found in tumors, we looked for a natural source to obtain large amounts of the N-terminal fragment. To this end, we established patient-derived xenografts (PDX) from HER2-positive breast tumor samples. The tumor cells grown in mice retained the histopathological characteristics of the original tumor (Supplementary Figure S2) . Analysis of the HER2 species expressed by these tumor xenografts further supported that the expression Using lysates obtained from the PDX67, we performed a largescale immunoprecipitation with anti-HER2 antibodies, loaded the immunoprecipitate in a preparative gel and cut the band corresponding to the H2NTF (Supplementary Figure S3A) . Analysis of the tryptic peptides generated from this band by liquid chromatography coupled to electrospray-ion-trap mass spectrometry, showed the presence of peptides corresponding to four cleavage sites, located after amino acids G704, Q709, M774 and A775 (Supplementary Figure S3B and data not shown). Unfortunately, this technology does not allow to determine whether one of these sites is predominant. This result indicates that different proteases participate in the generation of H2NTFs with different C-termini. However, based on the current knowledge of the activity of HER2 receptors and on the results in Figure 2b , we assumed that all the H2NTFs are functionally equivalent and that H2NTF742 is likely a representative model to study the activity of these N-terminal fragments of HER2.
H2NTF742 interacts with full-length HER receptors
The interactions between HER receptors take place at the cell surface and they are stabilized by epidermal growth factor-like ligands. As H2NTF742 is transported to the cell surface (Figure 2e) , it could interact with HER receptors. To test this hypothesis, we analyzed the physical interaction of H2NTF742 with HER2, HER3 and HER4 in different cell lines by co-immunoprecipitation experiments. As shown in Figures 4a and b, H2NTF742 interacted with ectopically expressed and endogenous HER2 in HEK293 and BT474 cells, respectively.
In stably transfected MCF7 cells, the interaction of H2NTF72 with endogenous HER3 and HER4 was enhanced upon stimulation with HRG, a ligand for these receptors (Figure 4c and Supplementary Figure S4 ). This result was expected because of the known ability of epidermal growth factor-like ligands to stabilize interactions between HER receptors. Thus, co-immunoprecipitation experiments showed that H2NTF742 readily interacts with HER2 and with ligand-bound HER3 and HER4.
H2NTF742 acts as a dominant-negative form of HER2 To determine the functional consequence of the interaction of H2NTF with HER receptors, we analyzed the levels of phosphorylation of Erk1,2 and Akt, two central components of the mitogenactivated protein kinase and phosphoinositide 3-kinase pathways. As shown in Figure 5 , the expression of H2NTF742 attenuated both pathways upon treatment with HRG in BT474 as well as in MCF7 cells. The ratio H2NTF/HER2 in stably transfected BT474 cells is B1, that is, within the range observed in some breast cancer samples (see Figure 1a , samples 11 and 28). Therefore, we concluded that H2NTF is likely to act as a dominant negative receptor in breast cancers in which it is expressed at ratios H2NTF/ HER2 X1. Despite its dominant-negative effect, the expression of H2NTF742 did not impair the proliferation of BT474 cells (Supplementary Figure S5) , suggesting that higher levels of H2NTF742 expression would be required to inhibit the growth of these cells. Several attempts to generate BT474 cells expressing higher levels of H2NTF742 failed, indirectly supporting that high levels of the N-terminal fragment of HER2 impair cell growth.
Expression of H2NTF and response to anti-HER2 drugs Lapatinib and trastuzumab inhibit the growth of cells overexpressing HER2; 5, 20 accordingly, treatment with these drugs resulted in a dose-dependent inhibition of the growth of BT474 cells (Figure 6a ). Although the effect of lapatinib was similar in control cells and in cells expressing H2NTF742, the expression of the N-terminal HER2 fragment led to resistance to low concentrations of trastuzumab (Figure 6a) , probably because the antibody was sequestered by the inactive N-terminal fragment. Confirming this possibility, higher concentrations of trastuzumab (1 mg/ml) inhibited the growth of parental BT474 and BT474/H2NTF742 cells with similar efficacy (Figure 6a) .
Despite the result in vitro, expression of H2NTF742 did not translate in resistance to trastuzumab when the growth of BT474 cells was analyzed in xenografts (Figure 6b ). In fact, the sensitivity of BT474/H2NTF xenografts to trastuzumab was indistinguishable to that of control BT474/green fluorescent protein (GFP) cells (Figure 6b ). This result is consistent with the known ability of trastuzumab to induce ADCC in nude mice, which have functional macrophages and natural killer cells. 21 The binding of trastuzumab to H2NTF likely induces ADCC as efficiently as the binding of trastuzumab to full-length HER2.
Collectively, the results presented here show that H2NTF is a frequent naturally occurring truncated form of HER2 that attenuates HER2 signaling. However, the expression of H2NTF is expected to impair cell proliferation at high (4 41) H2NTF/HER2 ratios. H2NTF induces resistance to trastuzumab in vitro but not in nude mice, indicating that the binding of the antibody to the N-terminal fragment induces ADCC as efficiently as that to the full-length molecule.
DISCUSSION
Recently, monoclonal antibodies directed against the amino terminus of a constitutively active carboxy terminal fragment of HER2, 100-115 kDa p95HER2 or 611-CTF, have been generated. The anti-p95HER2 antibodies recognize the epitopes exposed in the 100-115 kDa p95HER2 but masked in the native full-length molecule. 9, 10 During the characterization of one of these antip95HER2 antibodies, 32H2 (see Figure 1b) , we observed the existence of an amino-terminal fragment of HER2, H2NTF (Figure 1 ). This fragment is larger than herstatin, an autoinhibitory fragment of HER2 that does not contain the epitope recognized by 32H2. 22 The analysis of peptides from H2NTF points to the existence of several cleavage sites and, likely, to the participation of different proteases (Figure 3b ). It has been proposed that caspases cleave the intracellular domain of HER2. 11, 13 In fact, it has been shown that Caspase-8 cleaves HER2 at residues D1087 and D1125, making it unlikely that this caspase is responsible for the generation of the H2NTF observed in human breast cancers. 11, 13 Further, none of the putative cleavage sites found includes an aspartic residue, indicating that the protease(s) responsible for the generation of H2NTFs does(do) not belong to the caspase family.
Calpain has been proposed to cleave HER2 at an intracellular region close to the plasma membrane 12 that, in principle, could correspond to the cleavage sites identified in this report. Even though, since we have not detected high levels of the H2NTF in any cell line analyzed, we could not test the effect of calpain inhibitors on the generation of the fragment. The establishment of PDXs, in which high levels of H2NTF are detected (Figure 3a) , will allow the identification of the protease responsible for the generation of H2NTF in the future.
Acting as a dominant negative, H2NTF weakens HER receptor signaling as determined by the levels of activation of the mitogenactivated protein kinase and phosphoinositide 3-kinase-Akt pathways ( Figure 5 ). However, this attenuation is not enough to impair the proliferation of BT474 cells, suggesting that only when H2NTF is expressed at high levels, that is, when the ratio H2NTF/ HER2 is 4 41, the dominant negative effect of H2NTF impairs cell proliferation.
Out of 75 breast cancer samples analyzed, 12 (16%) showed ratios H2NTF/HER2 42 (Supplementary Table SI) . It could be predicted that, compared with tumors expressing low levels of H2NTF, these tumors would have weaker HER2 signaling and, therefore, a better prognosis. Nevertheless most, if not all, of these tumors were positive for p95HER2 (data not shown), indicating the existence of a compensatory mechanism to maintain high levels of HER2 signaling despite the generation of H2NTF.
In summary, here we describe the existence of a novel HER2 fragment, frequently expressed in breast cancers, that acts as a dominant negative. The future identification of the protease responsible for the generation of this fragment will help to definitively establish its role in HER2 signaling and breast cancer progression.
MATERIALS AND METHODS Materials
Primary antibodies included HER2 (CB11, BioGenex, San Ramon, CA, USA; and L87, Thermo Fisher Scientific, Huntsville, AL, USA), p-ERK1/2 (T202/ Y204), Erk1/2, P-Akt (S473), Akt, pHER3 (Y1289) (Cell Signaling Technology, Danvers, MA, USA), HA (Abcam, Cambridge, MA, USA), FLAG, pancytokeratin (Sigma, St Louis, MO, USA) and HER3 (NeoMarkers, Fremont, CA, USA). In-house-developed antibody 32H2 has been described before. 10 The anti-HER4 antibody was described in Sanchez-Martin et al. 
Plasmids
All plasmid constructs of HER2 were derived from a cDNA clone identical to the published sequence gi:183986. The different cDNA constructs in pCDNA3.1( þ ) (Invitrogen Ltd) and pUHD10-3 plasmids were made using standard PCR, sequencing and cloning techniques. NTF742 was also cloned into the NotI/XhoI sites of the pLEX lentiviral vector (Thermo Fisher Scientific).
Cell culture and viruses HEK293T, BT474, SKBR3, MDA-MB-361 and MDA-MD-453 were obtained from ATCC-LGC Standards (Teddington, UK) and MKN7 from Riken Cell Bank (Tsukuba, Japan). All cell lines were routinely maintained as recommended by the providers. MCF7 Tet-Off/NTF742 cells were generated and maintained as previously described. 8 For lentiviral production, HEK293T cells were transfected with the pLEX-JRedTurboGFP or pLEX-NTF742 using Arrest-In transfection reagent (Thermo Fisher Scientific) following the manufacturers protocol. For viral infections, viral supernatant was applied to BT474 cells in the presence of 8 mg/ml polybrene (Sigma). To obtain stable expressing cell lines, infected cells were put under puromycin selection (1 mg/ml) 48 h after infection.
Protein extraction, immunoprecipitation and immunoblotting
Cells were washed twice with ice-cold 1X phosphate-buffered saline (PBS) and proteins were extracted with 20 mM Tris-HCl pH 7.4, 137 mM NaCl, 2 mM EDTA, 10% glycerol, 1% Nonidet P-40 supplemented with 50 mg/ml leupeptin, 50 mg/ml aprotinin, 0.5 mM sodium orthovanadate and 1 mM phenylmethylsulfonyl fluoride. Breast tumor samples were homogenized in the same lysis buffer with a Polytron instrument. Protein extracts were quantified using bicinchoninic acid protein assay reagent (Pierce, Rockford, IL, USA), resolved by SDS-polyacrylamide gel electrophoresis and transferred to nitrocellulose membranes. Proteins were detected with Immobilon western chemiluminescent HRP substrate (Millipore, Billerica, MA, USA). Glycosylation was examined as described before. 8 For immunoprecipitation, equal amounts of protein extracts from untreated or HRG-treated cells were incubated 3 h with immunoglobulin G (Millipore), HA (Abcam), FLAG (Sigma) or CB11 (BioGenex) antibodies. Immunocomplexes were recovered by adding protein A-agarose beads (Millipore) for 2 h. Immunoprecipitates were washed thoroughly with lysis buffer before boiling in reducing conditions and analyzing by western blot. Where appropriate, signals in western blots were quantified with the software ImageJ 1.38 (NIH, Bethesda, MD, USA). , mice were randomized and treated with or without trastuzumab (n ¼ 6 per group). Tumor volume was determined at the indicated timepoints.
Proliferation assay 1 Â 10 3 BT474 cells were seeded per well in 96-well plates and treated as indicated in the corresponding figure. After 7 days, medium was removed and adherent cells were fixed in 10% glutaraldehyde for 10 min, then washed thrice in distilled water and stained with 0.1% crystal violet for 20 min. After washing, the stain was dissolved with 10% acetic acid and subsequently quantified at 570 nm.
Confocal microscopy
Cells were seeded on glass coverslips, washed with 1X PBS, fixed with 4% paraformaldehyde for 20 min and permeabilized with 0.2% Triton X-100 for 10 min. PBS with 1% bovine serum albumin, 0.1% saponin and 0.02% NaN 3 was used for blocking (1 h), primary antibody binding (2 h) and secondary fluorochrome-conjugated antibody binding (40 min in dark). Preparations were mounted using Vectashield with 4 0 ,6 0 -diamidino-2-phenylindole (Vector Laboratories, Burlingame, CA, USA). All procedures were performed at room temperature. Images were captured using an Olympus FV1000 confocal microscope (Olympus Corporation, Tokyo, Japan).
Patient tumor samples
Breast tumors used in this study were from surgical resections at Vall d'Hebron University Hospital and were obtained following the institutional guidelines. Written informed consent for the performance of tumor molecular studies was obtained from all patients who provided tissue. Diagnosis and histopathologic characteristics were confirmed by a pathologist.
Patient and cell line-derived xenografts
Six to eight-week old NOD.CB17PrkdcSCID/J (NOD/SCID) and BALB/c athymic mice were purchased from Charles River Laboratories (Paris, France). Mice were maintained and treated in accordance with institutional guidelines of Vall d'Hebron University Hospital Care and Use Committee. Fragments of patient samples were either implanted subcutaneously or digested with collagenase IA for 1-2 h before injection in combination with 1:1 Matrigel (BD Biosciences, Heidelberg, Germany) into the number four fat pad of NOD/SCID mice. 17 b-estradiol (1 uM) (Sigma) was added to drinking water.
For BT474 xenografts, a 17 b-estradiol pellet (Innovative Research of America, Sarasota, FL, USA) was inserted subcutaneously into each mouse 1 day before cell injection. A total of 1 Â 10 7 cells was injected into the right flanks and treatment began when tumors reached an average size of 4300 mm 3 . Trastuzumab (10 mg/kg in sterile PBS) or sterile PBS (control) was given intraperitoneally twice weekly. Tumor xenografts were measured with callipers every 3 days, and tumor volume was determined using the formula: (length Â width2) Â (pi/6). At the end of the experiment, the animals were anesthetized with a 1.5% isofluorane-air mixture and were killed by cervical dislocation. Results are presented as mean ± s.d. of tumor volume.
Immunohistochemistry
Tumor xenografts were removed, fixed overnight with 4% formol and then paraffin-embedded. Sequential 5-mm-thick slices were then obtained, hematoxylin-eosin-stained and immunostained for estrogen receptor, progesterone receptor (both from Novocastra, Milton Keynes, UK), c-erb-B2, Ki67 (both from Dako, Glostrup, Denmark) and 32H2. 10 Liquid chromatography-Mass spectrometric analysis
The SDS-polyacrylamide gel electrophoresis gel bands were cut and digested using modified porcine trypsin (Promega, Madison, WI, USA). Digests were analyzed on an LTQ Velos-Orbitrap mass spectrometer (Thermo Fisher Scientific, Bremen, Germany), coupled to a nano-HPLC system (Proxeon, Odense, Denmark). Peptide mixtures were initially concentrated on an EASY-column, 2 cm long, 100 mm id and packed with Reprosil C18, 5 mm particle size (Proxeon) and subsequently loaded onto an EASY-column, 75 mm id, 10 cm long and packed with Reprosil, 3 mm particle size (Proxeon). An acetonitrile gradient (5-35% ACN/0.1% formic acid in water, in 25 min, flow rate ca. 300 nl/min) was used to elute the peptides through a stainless steel nano-bore emitter (Proxeon) onto the nanospray ionization source of the mass spectrometer. MS/MS fragmentation spectra (200 ms, 100-2800 m/z) of the 20 most intense ions as detected from a 500 ms MS survey scan (300-1500 m/z), were acquired. A minimum intensity threshold of 1000 counts, exclusion of single-charged ions and a dynamic exclusion time of 20 s were used for precursor selection. Proteins were identified using Mascot (Matrix Science, London, UK) to search the Swiss-Prot 2010.11 database. MS/MS spectra were searched with a precursor mass tolerance of 10 p.p.m. (Orbitrap measurements were performed enabling the lock mass option (m/z 445.120024) to improve mass accuracy), fragment tolerance of 0.7 Da, trypsin or semitrypsin specificity, with a maximum of two missed cleavages, cysteine carbamidomethylation set as fixed modification and methionine oxidation as variable modification. Positive identification criterion was set as an individual Mascot score for each peptide MS/MS spectrum higher than the corresponding identity threshold score.
